To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

Research Grid, the AI startup that helps medical research institutions automate back-office admin for clinical trials, has ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Two tragic incidents in Phuket resulted in the drowning deaths of a five year old Chinese boy and a 43 year old British tourist, police confirmed yesterday. Karon Police were notified by Chalong ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...